These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 12006716)

  • 1. Suppression of puberty in girls with short-acting intranasal versus subcutaneous depot GnRH agonist.
    Tuvemo T; Gustafsson J; Proos LA;
    Horm Res; 2002; 57(1-2):27-31. PubMed ID: 12006716
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Variations in pituitary-gonadal suppression during intranasal buserelin and intramuscular depot-triptorelin therapy for central precocious puberty. Belgian Study Group for Pediatric Endocrinology.
    Heinrichs C; Craen M; Vanderschueren-Lodeweyckx M; Malvaux P; Fawe L; Bourguignon JP
    Acta Paediatr; 1994 Jun; 83(6):627-33. PubMed ID: 7919761
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term effectiveness of depot gonadotropin-releasing hormone analogue in the treatment of children with central precocious puberty.
    Clemons RD; Kappy MS; Stuart TE; Perelman AH; Hoekstra FT
    Am J Dis Child; 1993 Jun; 147(6):653-7. PubMed ID: 8506834
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Comparison between complete and incomplete suppression of the hypophyseal-gonadal axis in girls with central precocious puberty: effect on growth and prospective final height].
    Partsch CJ; Hümmelink R; Sippell WG; Oostdijk W; Odink RJ; Drop SL
    Monatsschr Kinderheilkd; 1993 Dec; 141(12):935-9. PubMed ID: 8114776
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intranasal and subcutaneous treatment of central precocious puberty in both sexes with a long-acting analog of luteinizing hormone-releasing hormone.
    Luder AS; Holland FJ; Costigan DC; Jenner MR; Wielgosz G; Fazekas AT
    J Clin Endocrinol Metab; 1984 Jun; 58(6):966-72. PubMed ID: 6427266
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum insulin-like growth factor I (IGF-I) and IGF-binding protein 3 levels are increased in central precocious puberty: effects of two different treatment regimens with gonadotropin-releasing hormone agonists, without or in combination with an antiandrogen (cyproterone acetate).
    Juul A; Scheike T; Nielsen CT; Krabbe S; Müller J; Skakkebaek NE
    J Clin Endocrinol Metab; 1995 Oct; 80(10):3059-67. PubMed ID: 7559897
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Suppression of puberty with long-acting goserelin (Zoladex-LA): effect on gonadotrophin response to GnRH in the first treatment cycle.
    Trueman JA; Tillmann V; Cusick CF; Foster P; Patel L; Hall CM; Price DA; Clayton PE
    Clin Endocrinol (Oxf); 2002 Aug; 57(2):223-30. PubMed ID: 12153601
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term results of GnRH analogue (Buserelin) treatment in girls with central precocious puberty.
    Brauner R; Thibaud E; Bischof P; Sizonenko PC; Rappaport R
    Acta Paediatr Scand; 1985 Nov; 74(6):945-9. PubMed ID: 3937430
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The treatment of central precocious puberty using an intranasal LHRH analogue (buserelin).
    Stanhope R; Adams J; Brook CG
    Clin Endocrinol (Oxf); 1985 Jun; 22(6):795-806. PubMed ID: 3926352
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of central precocious puberty with an intranasal analogue of GnRH (Buserelin).
    Bourguignon JP; Van Vliet G; Vandeweghe M; Malvaux P; Vanderschueren-Lodeweyckx M; Craen M; Du Caju MV; Ernould C
    Eur J Pediatr; 1987 Nov; 146(6):555-60. PubMed ID: 3123239
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A single luteinizing hormone determination 2 hours after depot leuprolide is useful for therapy monitoring of gonadotropin-dependent precocious puberty in girls.
    Brito VN; Latronico AC; Arnhold IJ; Mendonca BB
    J Clin Endocrinol Metab; 2004 Sep; 89(9):4338-42. PubMed ID: 15356030
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The histrelin implant: a novel treatment for central precocious puberty.
    Hirsch HJ; Gillis D; Strich D; Chertin B; Farkas A; Lindenberg T; Gelber H; Spitz IM
    Pediatrics; 2005 Dec; 116(6):e798-802. PubMed ID: 16322137
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetic characteristics of the gonadotropin-releasing hormone analog D-Ser(TBU)-6EA-10luteinizing hormone-releasing hormone (buserelin) after subcutaneous and intranasal administration in children with central precocious puberty.
    Holland FJ; Fishman L; Costigan DC; Luna L; Leeder S
    J Clin Endocrinol Metab; 1986 Nov; 63(5):1065-70. PubMed ID: 3093518
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Suppression of gonadotropin secretion by a long-acting gonadotropin-releasing hormone analog (leuprolide acetate, Lupron Depot) in children with precocious puberty.
    Kappy M; Stuart T; Perelman A; Clemons R
    J Clin Endocrinol Metab; 1989 Nov; 69(5):1087-9. PubMed ID: 2507570
    [TBL] [Abstract][Full Text] [Related]  

  • 15. More basic isoforms of serum gonadotropins during gonadotropin-releasing hormone agonist therapy in pubertal children.
    Wide L; Albertsson-Wikland K; Phillips DJ
    J Clin Endocrinol Metab; 1996 Jan; 81(1):216-21. PubMed ID: 8550754
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Short-term comparison of the treatment of precocious puberty with 2 different LHRH antagonists (buserelin and long-acting triptorelin). An endocrinologic and echographic study].
    Cicognani A; Cacciari E; Balsamo A; Cassio A; Papasodero A; Bellizzi M; Guacci P; Zappulla F
    Pediatr Med Chir; 1994; 16(1):43-8. PubMed ID: 8029088
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Final height in girls with central precocious puberty: comparison of two different luteinizing hormone-releasing hormone agonist treatments.
    Antoniazzi F; Cisternino M; Nizzoli G; Bozzola M; Corrias A; De Luca F; De Sanctis C; Rigon F; Zamboni G; Bernasconi S
    Acta Paediatr; 1994 Oct; 83(10):1052-6. PubMed ID: 7841703
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term treatment of central precocious puberty with an intranasal LHRH analogue: control of pituitary function by urinary gonadotropins.
    Rime JL; Zumsteg U; Blumberg A; Hadziselimovic F; Girard J; Zurbrügg RP
    Eur J Pediatr; 1988 Apr; 147(3):263-9. PubMed ID: 3134243
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Depot gonadotropin-releasing hormone agonist blunts the androgen-induced suppression of spermatogenesis in a clinical trial of male contraception.
    Behre HM; Nashan D; Hubert W; Nieschlag E
    J Clin Endocrinol Metab; 1992 Jan; 74(1):84-90. PubMed ID: 1727833
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diagnosis and treatment of central precocious puberty--can final height be improved? German/Dutch Central Precocious Puberty Study Group.
    Sippell WG
    Horm Res; 1994; 41 Suppl 2():14-5. PubMed ID: 8088698
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.